Highlights CNS Pharmaceuticals, Inc.

Equities

CNSP

US18978H2013

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-29 pm EDT			5-day change	1st Jan Change
0.215 ^USD	0.00%		+7.99%	-83.07%

Apr. 23	Transcript : CNS Pharmaceuticals, Inc. - Special Call
Apr. 01	CNS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CNS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday on Caution Ahead of Fed Meeting, Tech Earnings	Jan. 30	MT
CNS Pharmaceuticals, Inc. Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme	Jan. 17	CI
CNS Pharmaceuticals, Inc. Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin	Dec. 18	CI
CNS Pharmaceuticals, Inc. Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy	Nov. 22	CI
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
CNS Pharmaceuticals, Inc. Opens 46 Clinical Trial Sites Across the U.S., Italy, France, Spain, and Switzerland	23-10-11	CI
Cns Pharmaceuticals, Inc. Announces Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme	23-09-07	CI
CNS Pharmaceuticals, Inc. Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy	23-08-14	CI
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
CNS Pharmaceuticals, Inc. Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme	23-08-03	CI
CNS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
CNS Pharmaceuticals, Inc. Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of Gbm with First Patient Enrolled in Switzerland	23-03-09	CI
Jazz Pharma ruling clears U.S. roadblock for rival narcolepsy drug	23-02-24	RE
CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM	23-02-07	CI
CNS Pharmaceuticals, Inc. Announces Investigator-Initiated Phase 1B/2 Trial to Be Conducted At the Pomeranian Medical University in Poland	23-01-12	CI
CNS Pharmaceuticals, Inc Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme	22-12-08	CI
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
CNS Pharmaceuticals, Inc. Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM	22-11-02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights CNS Pharmaceuticals, Inc.

Equities

CNSP

US18978H2013

Highlights

Filters